Photo from wikipedia
The pathogenesis of pityriasis rubra pilaris (PRP) is not completely understood, but interleukin (IL)‐17 has been shown to play a critical role. There are no reliable immunomodulatory agents to treat… Click to show full abstract
The pathogenesis of pityriasis rubra pilaris (PRP) is not completely understood, but interleukin (IL)‐17 has been shown to play a critical role. There are no reliable immunomodulatory agents to treat PRP. We conducted an open‐label, single‐arm clinical trial of secukinumab, a monoclonal antibody that inhibits IL‐17A, for the treatment of PRP.
Keywords:
rubra pilaris;
arm clinical;
single arm;
clinical trial;
pityriasis rubra
Journal Title: British Journal of Dermatology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: British Journal of Dermatology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!